ABEO
Abeona Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.00
+1.18%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
Market Cap
$343.10M
MomentumView details →
1D Return
+1.18%
YTD Return
+12.24%
RSI (14)
41.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
Market Cap
$343.10M
RSI (14)
41.9
MomentumView details →
1D Return
+1.18%
YTD Return
+12.24%
SummaryUpdated Jun 1, 2026
Abeona Therapeutics Inc. (NASDAQ:ABEO) is a clinical-stage biopharmaceutical company founded in 1974 and headquartered in New York, New York. Originally incorporated as PlasmaTech Biopharmaceuticals, the company changed its name to Abeona Therapeutics in June 2015. The company specializes in developing gene and cell therapies for life-threatening rare genetic diseases. In April 2025, Abeona achieved a major milestone with the FDA approval of <b>ZEVASKYN</b>, marking the first autologous cell-based gene therapy approved for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder.
Similar companies
Latest newsMore news →
Abeona Therapeutics reported second-quarter revenue growth from its ZEVASKYN cell therapy launch, while noting operational challenges in patient scheduling and manufacturing that affected revenue recognition.22d agoAbeona Therapeutics Inc. activated Cincinnati Children's as the seventh Qualified Treatment Center for ZEVASKYN.45d agoMichael Amoroso resigned from the Board of Directors of Abeona Therapeutics Inc., effective June 11, 2026.85d ago